04/04/14, Research and Development Bayer to Present New Data on Advancing Oncology Portfolio New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development more
02/10/14, Research and Development Two-Year Results From Phase III Trial of VEGF Trap-Eye (aflibercept solution for injection) for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision more
|Research expenses 2013||EUR 1,654 million|
|In percent of division sales 2013
|Employees in Research & Development||7,800
(as of Dec 31, 2013)
|Main research sites||Berlin and Wuppertal, Germany and Berkeley, USA|
We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.